BIIB Valuation

Biogen Inc

Add to Watchlist

Advanced Chart

137.500

-1.1(-0.794%)1D

Overview
Forecast
Valuation
Earnings

BIIB Relative Valuation

BIIB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIIB is overvalued; if below, it's undervalued.

Historical Valuation

Biogen Inc (BIIB) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.03 is considered Undervalued compared with the five-year average of 14.07. The fair price of Biogen Inc (BIIB) is between 167.09 to 251.28 according to relative valuation methord. Compared to the current price of 138.60 USD , Biogen Inc is Undervalued By 17.05%.

Relative Value

Fair Zone

167.09-251.28

Current Price：138.60

17.05%

Undervalued

9.03

Trailing

Forward

6.37

EV/EBITDA

Biogen Inc. (BIIB) has a current EV/EBITDA of 6.37. The 5-year average EV/EBITDA is 10.23. The thresholds are as follows: Strongly Undervalued below 5.34, Undervalued between 5.34 and 7.79, Fairly Valued between 12.68 and 7.79, Overvalued between 12.68 and 15.13, and Strongly Overvalued above 15.13. The current Forward EV/EBITDA of 6.37 falls within the Undervalued range.

8.59

EV/EBIT

Biogen Inc. (BIIB) has a current EV/EBIT of 8.59. The 5-year average EV/EBIT is 12.42. The thresholds are as follows: Strongly Undervalued below 7.03, Undervalued between 7.03 and 9.72, Fairly Valued between 15.12 and 9.72, Overvalued between 15.12 and 17.81, and Strongly Overvalued above 17.81. The current Forward EV/EBIT of 8.59 falls within the Undervalued range.

2.14

Biogen Inc. (BIIB) has a current PS of 2.14. The 5-year average PS is 3.49. The thresholds are as follows: Strongly Undervalued below 1.96, Undervalued between 1.96 and 2.73, Fairly Valued between 4.26 and 2.73, Overvalued between 4.26 and 5.03, and Strongly Overvalued above 5.03. The current Forward PS of 2.14 falls within the Undervalued range.

7.49

P/OCF

Biogen Inc. (BIIB) has a current P/OCF of 7.49. The 5-year average P/OCF is 11.71. The thresholds are as follows: Strongly Undervalued below 6.37, Undervalued between 6.37 and 9.04, Fairly Valued between 14.39 and 9.04, Overvalued between 14.39 and 17.06, and Strongly Overvalued above 17.06. The current Forward P/OCF of 7.49 falls within the Undervalued range.

7.56

P/FCF

Biogen Inc. (BIIB) has a current P/FCF of 7.56. The 5-year average P/FCF is 13.47. The thresholds are as follows: Strongly Undervalued below 7.13, Undervalued between 7.13 and 10.30, Fairly Valued between 16.65 and 10.30, Overvalued between 16.65 and 19.82, and Strongly Overvalued above 19.82. The current Forward P/FCF of 7.56 falls within the Undervalued range.

Biogen Inc (BIIB) has a current Price-to-Book (P/B) ratio of 1.15. Compared to its 3-year average P/B ratio of 2.20 , the current P/B ratio is approximately -47.74% higher. Relative to its 5-year average P/B ratio of 2.77, the current P/B ratio is about -58.40% higher. Biogen Inc (BIIB) has a Forward Free Cash Flow (FCF) yield of approximately 10.00%. Compared to its 3-year average FCF yield of 6.08%, the current FCF yield is approximately 64.55% lower. Relative to its 5-year average FCF yield of 7.33% , the current FCF yield is about 36.47% lower.

1.15

P/B

Median3y

2.20

Median5y

2.77

10.00

FCF Yield

Median3y

6.08

Median5y

7.33

Competitors Valuation Multiple

The average P/S ratio for BIIB's competitors is 10.05, providing a benchmark for relative valuation. Biogen Inc Corp (BIIB) exhibits a P/S ratio of 2.14, which is -78.73% above the industry average. Given its robust revenue growth of 7.33%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

United Therapeutics Corp

Performance Decomposition

Market capitalization of BIIB decreased by 32.31% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.46B to 2.65B.

The secondary factor is the Margin Expansion, contributed 1.35%to the performance.

Overall, the performance of BIIB in the past 1 year is driven by Revenue Growth. Which is more sustainable.

7.33%

2.46B → 2.65B

Revenue Growth

1.35%

23.68 → 24.00

Margin Expansion

-40.99%

22.47 → 13.26

P/E Change

-32.31%